These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9758241)

  • 1. Sibutramine and energy balance.
    Astrup A; Hansen DL; Lundsgaard C; Toubro S
    Int J Obes Relat Metab Disord; 1998 Aug; 22 Suppl 1():S30-5; discussion S36-7, S42. PubMed ID: 9758241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Sibutramine, an upcoming drug for weight loss acting on energy consumption and energy expenditure].
    Astrup A
    Acta Med Austriaca; 1998; 25(4-5):146-9. PubMed ID: 9879391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What do pharmacological approaches to obesity management offer? Linking pharmacological mechanisms of obesity management agents to clinical practice.
    Astrup A; Lundsgaard C
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():29-34. PubMed ID: 9792479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine.
    Heal DJ; Aspley S; Prow MR; Jackson HC; Martin KF; Cheetham SC
    Int J Obes Relat Metab Disord; 1998 Aug; 22 Suppl 1():S18-28; discussion S29. PubMed ID: 9758240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How does sibutramine work?
    Lean ME
    Int J Obes Relat Metab Disord; 2001 Dec; 25 Suppl 4():S8-11. PubMed ID: 11916106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action.
    Nisoli E; Carruba MO
    Obes Rev; 2000 Oct; 1(2):127-39. PubMed ID: 12119986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females.
    Walsh KM; Leen E; Lean ME
    Int J Obes Relat Metab Disord; 1999 Oct; 23(10):1009-15. PubMed ID: 10557020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
    Van Gaal LF; Wauters MA; De Leeuw IH
    Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():35-40. PubMed ID: 9792480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction.
    Hansen DL; Toubro S; Stock MJ; Macdonald IA; Astrup A
    Int J Obes Relat Metab Disord; 1999 Oct; 23(10):1016-24. PubMed ID: 10557021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Locomotion is the major determinant of sibutramine-induced increase in energy expenditure.
    Golozoubova V; Strauss F; Malmlöf K
    Pharmacol Biochem Behav; 2006 Apr; 83(4):517-27. PubMed ID: 16647108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A benefit-risk assessment of sibutramine in the management of obesity.
    Nisoli E; Carruba MO
    Drug Saf; 2003; 26(14):1027-48. PubMed ID: 14583064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sibutramine and the management of obesity.
    Poston WS; Foreyt JP
    Expert Opin Pharmacother; 2004 Mar; 5(3):633-42. PubMed ID: 15013931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Signalling in body-weight homeostasis: neuroendocrine efferent signals.
    Webber J; Macdonald IA
    Proc Nutr Soc; 2000 Aug; 59(3):397-404. PubMed ID: 10997655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sibutramine and the sympathetic nervous system in obese humans.
    Haynes WG; Egri Z
    Clin Auton Res; 2005 Jun; 15(3):189-92. PubMed ID: 15944867
    [No Abstract]   [Full Text] [Related]  

  • 16. The effect of sibutramine on energy expenditure and body composition in obese adolescents.
    Van Mil EG; Westerterp KR; Kester AD; Delemarre-van de Waal HA; Gerver WJ; Saris WH
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1409-14. PubMed ID: 17264187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sibutramine: a review of the pharmacology of a novel anti-obesity agent.
    Stock MJ
    Int J Obes Relat Metab Disord; 1997 Mar; 21 Suppl 1():S25-9. PubMed ID: 9130038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thermogenic effects of sibutramine in humans.
    Hansen DL; Toubro S; Stock MJ; Macdonald IA; Astrup A
    Am J Clin Nutr; 1998 Dec; 68(6):1180-6. PubMed ID: 9846844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of anti-obesity activity of duloxetine in comparison with sibutramine along with its anti-depressant activity: an experimental study in obese rats.
    Chudasama HP; Bhatt PA
    Can J Physiol Pharmacol; 2009 Nov; 87(11):900-7. PubMed ID: 19935897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women.
    Halford JC; Boyland EJ; Cooper SJ; Dovey TM; Huda MS; Dourish CT; Dawson GR; Wilding JP
    J Psychopharmacol; 2010 Jan; 24(1):99-109. PubMed ID: 18755818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.